medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-27-36-40medalphabet-3413Research ArticleСтатьиПервый российский опыт применения комбинации ниволумаба и ипилимумаба в первой линии лечения неоперабельной мезотелиомы плеврыClinical case of using combination of nivolumab and ipilimumab in first line of treatment for inoperable pleural mesotheliomahttps://orcid.org/0000-0002-4548-1026БарболинаТ. Д.BarbolinaT. D.

Барболина Татьяна Дмитриевна, врач-онколог, к.м.н., н.с. онкологического отделения лекарственных методов лечения (химиотерапевтическое) № 3; ассистент кафедры онкологии факультета постдипломного дополнительного образования

Москва.

Barbolina Tatyana D., oncologist, PhD Med, research associate at Oncology Dept of Medicinal Methods of Treatment (Chemotherapeutic) No. 3; assistant at Dept of Oncology of the Faculty of Postgraduate Additional Education

Moscow.

katan4ik@list.ruhttps://orcid.org/0000-0003-2981-7666БагроваС. Г.BagrovaS. G.

Багрова Светлана Геннадиевна, врач-онколог, к.м.н., н.с. онкологического отделения лекарственных методов лечения (химиотерапевтическое) № 1

Москва.

Bagrova Svetlana G., oncologist, PhD Med, research associate at Oncology Dept of Medicinal Methods of Treatment (Chemotherapeutic) No. 1

Moscow.

s.bagrova@mail.ruМандринаМ. О.MandrinaM. O.

Мандрина Марьяна Олеговна, врач-онколог онкологического отделения хирургических методов лечения № 16

Москва.

Mandrina Mariana O., oncologist at Oncology Dept of Surgical Methods of Treatment No. 16

Moscow.

minavasaya@mail.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава России; ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n.a. N.N. Blokhin; Moscow State University of Medicine and Dentistry n.a. A.I. EvdokimovRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n.a. N.N. BlokhinRussian Federation202304122023027Диагностика и онкотерапия (3)3640Copyright © Барболина Т.Д., Багрова С.Г., Мандрина М.О., 20232023Барболина Т.Д., Багрова С.Г., Мандрина М.О.Barbolina T.D., Bagrova S.G., Mandrina M.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3413

Цитостатическая терапия до настоящего времени оставалась «золотым стандартом» лечения неоперабельной мезотелиомы плевры с продолжительностью жизни около 9–18 месяцев. В статье представлен клинический случай успешного применения ингибиторов иммунных контрольных точек в первой линии лечения неоперабельной злокачественной мезотелиомы плевры и тактика коррекции иммуноопосредованных осложнений у относительно пожилой пациентки.

Cytostatic therapy still remains the gold standard for the treatment of inoperable pleural mesothelioma with a life expectancy of about 9–18 months. The article presents the results of the use of immune checkpoint inhibitors in the first treatment line for inoperable malignant pleural mesothelioma and management of immune-related adverse events in an elderly patient.

мезотелиома плеврыдвойная иммунотерапияблокаторы иммунных контрольных точеклекарственное лечение злокачественной мезотелиомыиммуноопосредованные осложненияиммуноопосредованный нефритPleural mesotheliomadual immunotherapyimmune checkpoint inhibitorsdrug treatment of malignant mesotheliomaimmunerelated adverse effectrenal immune-related adverse effectReferencesVogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.Kindler HL, Ismaila N, Armato SG III, et al: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018; 36: 1343–1373.Kindler HL, Ismaila N, Armato SG III, et al: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018; 36: 1343–1373.Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756–63.Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756–63.Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370–3.Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370–3.Dudek AZ, Wang X, Gu L, et al: Randomized phase 2 study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first line chemotherapy: Cancer and Leukemia Group B30901 (Alliance). Clin Lung Cancer 2020; 21: 553–561.Dudek AZ, Wang X, Gu L, et al: Randomized phase 2 study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first line chemotherapy: Cancer and Leukemia Group B30901 (Alliance). Clin Lung Cancer 2020; 21: 553–561.Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25–30.Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25–30.Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97: 2791–7.Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97: 2791–7.Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28: 223–6.Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28: 223–6.van Haarst JM, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342–5.van Haarst JM, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342–5.Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405–14.Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405–14.Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma: Phase II Results from the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol 2017; 35: 3591–600.Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma: Phase II Results from the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol 2017; 35: 3591–600.de Gooijer C.J., Baas P., Burgers J.A. Current chemotherapy strategies in malignant pleural mesothelioma. Transl. Lung Cancer Res. 2018, Oct. Vol. 7, No. 5. P. 574–583.de Gooijer C.J., Baas P., Burgers J.A. Current chemotherapy strategies in malignant pleural mesothelioma. Transl. Lung Cancer Res. 2018, Oct. Vol. 7, No. 5. P. 574–583.Mansfield AS et al. B7-H1 expression in malignant pleural mesothelioms is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014; 9 (7): 1036–1040.Mansfield AS et al. B7-H1 expression in malignant pleural mesothelioms is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014; 9 (7): 1036–1040.Карпенко Т.Д. и др. Анализ экспрессии белка PD-L1 в клетках злокачественной мезотелиомы плевры. Российский онкологический журнал. 2018. Т. 23, № 1. С. 4–9. Karpenko T.D. et al. Analysis of PD-L1 protein expression in malignant pleural mesothelioma cells. Russian journal of oncology. 2018. Vol. 23, No. 1. P. 4–9.Карпенко Т.Д. и др. Анализ экспрессии белка PD-L1 в клетках злокачественной мезотелиомы плевры. Российский онкологический журнал. 2018. Т. 23, № 1. С. 4–9. Karpenko T.D. et al. Analysis of PD-L1 protein expression in malignant pleural mesothelioma cells. Russian journal of oncology. 2018. Vol. 23, No. 1. P. 4–9.Ettinger DS, Wood DE, Aiser DL, et al. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 1.2021. National Comprehensive Cancer Network. Accessed January 15, 2021.Ettinger DS, Wood DE, Aiser DL, et al. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 1.2021. National Comprehensive Cancer Network. Accessed January 15, 2021.Lievense L.A., Sterman D.H., Cornelissen R., Aerts J.G. Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2017; 196: 274–282.Lievense L.A., Sterman D.H., Cornelissen R., Aerts J.G. Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2017; 196: 274–282.Zhang F., Gong W. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesotheli-oma: A meta-analysis. Int. Immunopharmacol. 2020; 83: 106481.Zhang F., Gong W. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesotheli-oma: A meta-analysis. Int. Immunopharmacol. 2020; 83: 106481.Cedrés S., Ponce-Aix S., Zugazagoitia J., Sansano I., Enguita A., Navarro-Mendivil A., Martinez-Marti A., Martinez P., Felip E. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) PLoS ONE. 2015; 10: e0121071.Cedrés S., Ponce-Aix S., Zugazagoitia J., Sansano I., Enguita A., Navarro-Mendivil A., Martinez-Marti A., Martinez P., Felip E. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) PLoS ONE. 2015; 10: e0121071.Arnaud Scherpereelet, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT‑1501 MAPS 2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019; 20 (3): e132.Arnaud Scherpereelet, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT‑1501 MAPS 2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019; 20 (3): e132.Morihito Okada; Takashi Kijima, Keisuke Aoe; Terufumi Kato; Nobukazu Fujimoto et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res 2019; 25 (18): 5485–5492.Morihito Okada; Takashi Kijima, Keisuke Aoe; Terufumi Kato; Nobukazu Fujimoto et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res 2019; 25 (18): 5485–5492.Josine Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Sjaak Burgers, Wieneke Buikhuisen et al. Programmed Death 1 Blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 2018; 13 (10): 1569–1576.Josine Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Sjaak Burgers, Wieneke Buikhuisen et al. Programmed Death 1 Blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 2018; 13 (10): 1569–1576.Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE‑028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5): 623–630.Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE‑028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5): 623–630.Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE‑158 study. Lancet Respir Med. 2021; 9 (6): 613–621.Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE‑158 study. Lancet Respir Med. 2021; 9 (6): 613–621.Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O’Brien M. et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2020; 31 (12): 1734–1745.Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O’Brien M. et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2020; 31 (12): 1734–1745.Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2019; 30: v931.Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2019; 30: v931.Marcq E, Siozopoulou V, de Waele J, Van Audenaerde J, Zwaenepoel K, Santermans E. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. OncoImmunology. 2017; 6.Marcq E, Siozopoulou V, de Waele J, Van Audenaerde J, Zwaenepoel K, Santermans E. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. OncoImmunology. 2017; 6.Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013; 339: 286–291.Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013; 339: 286–291.Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in immune cell content in malignant pleural mesothelioma. Int J Mol Sci. 2018; 19.Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in immune cell content in malignant pleural mesothelioma. Int J Mol Sci. 2018; 19.Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017; 17: 475–488.Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017; 17: 475–488.Maio M., Scherpereel A., Calabrò L., Aerts J., Cedres S. et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18 (9): 1261–1273.Maio M., Scherpereel A., Calabrò L., Aerts J., Cedres S. et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18 (9): 1261–1273.Calabrò L., Rossi G., Morra A., Rosati C., Cutaia O. et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO‑1 study. Lancet Respir Med 2021; 9 (9): 969–976.Calabrò L., Rossi G., Morra A., Rosati C., Cutaia O. et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO‑1 study. Lancet Respir Med 2021; 9 (9): 969–976.Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019; 7(3): 260–270.Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019; 7(3): 260–270.Baas P., Scherpereel A., Nowak A, Fujimoto N, Peters S. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397 (10272): 375–386.Baas P., Scherpereel A., Nowak A, Fujimoto N, Peters S. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397 (10272): 375–386.

The authors declare that there are no conflicts of interest present.